Radiomic signature of 18F fluorodeoxyglucose PET/CT for prediction of gastric cancer survival and chemotherapeutic benefits
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
We aimed to evaluate whether radiomic feature-based fluorine 18 ( 18 F) fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging signatures allow prediction of gastric cancer (GC) survival and chemotherapy benefits.Methods: A total of 214 GC patients (training (n = 132) or validation (n = 82) cohort) were subjected to radiomic feature extraction (80 features).Radiomic features of patients in the training cohort were subjected to a LASSO cox analysis to predict disease-free survival (DFS) and overall survival (OS) and were validated in the validation cohort.A radiomics nomogram with the radiomic signature incorporated was constructed to demonstrate the incremental value of the radiomic signature to the TNM staging system for individualized survival estimation, which was then assessed with respect to calibration, discrimination, and clinical usefulness.The performance was assessed with concordance index (C-index) and integrated Brier scores.Results: Significant differences were found between the high-and low-radiomic score (Rad-score) patients in 5-year DFS and OS in training and validation cohorts.Multivariate analysis revealed that the Rad-score was an independent prognostic factor.Incorporating the Rad-score into the radiomics-based nomogram resulted in better performance (C-index: DFS, 0.800; OS, 0.786; in the training cohort) than TNM staging system and clinicopathologic nomogram.Further analysis revealed that patients with higher Rad-scores were prone to benefit from chemotherapy.Conclusion: The newly developed radiomic signature was a powerful predictor of OS and DFS.Moreover, the radiomic signature could predict which patients could benefit from chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yushkevich, P. A., Piven, J., Hazlett, H. C., Smith, R. G., Ho, S., Gee, J. C., & Gerig, G. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.01.015 · Cited by 8,868
Radiomics: Images Are More than Pictures, They Are Data
Gillies, R. J., Kinahan, P. E., & Hricak, H. (2016) · Radiology · doi:10.1148/radiol.2015151169 · Cited by 8,421
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
Aerts, H. J. W. L., Velazquez, E. R., Leijenaar, R. T. H., Parmar, C., Grossmann, P., Carvalho, S., Bussink, J., Monshouwer, R., Haibe-Kains, B., Rietveld, D., et al. (2014) · Nature Communications · doi:10.1038/ncomms5006 · Cited by 5,132
Radiomics: the process and the challenges
Kumar, V., Gu, Y., Basu, S., Berglund, A., Eschrich, S. A., Schabath, M. B., Forster, K., Aerts, H. J. W. L., Dekker, A., Fenstermacher, D., et al. (2012) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2012.06.010 · Cited by 2,258 · cited 1×
“By extracting a large number of putative imaging features, radiomics enables the noninvasive profiling of tumor heterogeneity, which may ultimately correlate with clinical outcomes [11-16].”
BackgroundSun, R., Limkin, E. J., Vakalopoulou, M., Dercle, L., Champiat, S., Han, S. R., Verlingue, L., Brandao, D., Lancia, A., Ammari, S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30413-3 · Cited by 1,236 · cited 1×
“In contrast, Radiomics refers to the comprehensive quantification of tumor phenotypes by applying a large number of quantitative image features, which may reflect changes of human tissues at the cellular and genetic levels and provide different information from TNM staging [11, 12, 38-41].”
BackgroundNoh, S. H., Park, S. R., Yang, H.-K., Chung, H. C., Chung, I.-J., Kim, S.-W., Kim, H.-H., Choi, J.-H., Kim, H.-K., Yu, W., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70473-5 · Cited by 1,049 · cited 3×
“Surgical resection remains the main curative method for GC, but the high rate of relapse in patients with advanced gastric cancer makes it important to consider adjuvant treatments [2-4].”
BackgroundCT-based radiomic signature predicts distant metastasis in lung adenocarcinoma
Coroller, T. P., Grossmann, P., Hou, Y., Rios Velazquez, E., Leijenaar, R. T. H., Hermann, G., Lambin, P., Haibe-Kains, B., Mak, R. H., & Aerts, H. J. W. L. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.02.015 · Cited by 695 · cited 2×
“This approach has provided insights for personalized medicine in oncological practices associated with tumor detection, prognosis, subtype classification, lymph node metastasis, distant metastasis, and therapeutic response evaluation in many types of cancer with widely available imaging data such as CT or 18F-FDG PET…”
BackgroundMcAlinden, C., Khadka, J., & Pesudovs, K. (2011) · Ophthalmic and Physiological Optics · doi:10.1111/j.1475-1313.2011.00851.x · Cited by 436 · cited 4×
“The strength of agreement was evaluated as follows: an ICC value of less than 0.20 indicated poor agreement; 0.21–0.40, fair agreement; 0.41–0.60, moderate agreement; 0.61–0.80, good agreement; and 0.81–1.0, excellent agreement [24].”
MethodInfluentialCheong, J.-H., Yang, H.-K., Kim, H., Kim, W. H., Kim, Y.-W., Kook, M.-C., Park, Y.-K., Kim, H.-H., Lee, H. S., Lee, K. H., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30108-6 · Cited by 219 · cited 2×
“Previous studies have shown that tumor infiltrated immune cells, microRNA and gene signatures were associated with chemotherapeutic response in GC [3, 48, 49].”
BackgroundJiang, Y., Chen, C., Xie, J., Wang, W., Zha, X., Lv, W., Chen, H., Hu, Y., Li, T., Yu, J., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.007 · Cited by 184 · cited 3×
“This approach has provided insights for personalized medicine in oncological practices associated with tumor detection, prognosis, subtype classification, lymph node metastasis, distant metastasis, and therapeutic response evaluation in many types of cancer with widely available imaging data such as CT or 18F-FDG PET…”
BackgroundSelf-citationLi, T.-J., Jiang, Y.-M., Hu, Y.-F., Huang, L., Yu, J., Zhao, L.-Y., Deng, H.-J., Mou, T.-Y., Liu, H., Yang, Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0617 · Cited by 179 · cited 1×
“Additionally, as more specific patients and tumor information becomes routinely collected in the future, such as genetic information and other molecular tumor markers, use of these types of predictive models will become increasingly important [3, 37, 47, 60].”
BackgroundSelf-citationAssociation of Adjuvant Chemotherapy With Survival in Patients With Stage II or III Gastric Cancer
Jiang, Y., Li, T., Liang, X., Hu, Y., Huang, L., Liao, Z., Zhao, L., Han, Z., Zhu, S., Wang, M., et al. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2017.1087 · Cited by 152 · cited 5×
“However, the survival rates for many patients were still low despite initial high response rates [4, 6].”
BackgroundInfluentialSelf-citationJiang, Y., Xie, J., Han, Z., Liu, W., Xi, S., Huang, L., Huang, W., Lin, T., Zhao, L., Hu, Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0848 · Cited by 143 · cited 2×
“Additionally, as more specific patients and tumor information becomes routinely collected in the future, such as genetic information and other molecular tumor markers, use of these types of predictive models will become increasingly important [3, 37, 47, 60].”
BackgroundSelf-citation
Cited by
Mayerhoefer, M. E., Materka, A., Langs, G., Häggström, I., Szczypiński, P., Gibbs, P., & Cook, G. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.222893 · Cited by 1,777
Jiang, Y., Zhou, K., Sun, Z., Wang, H., Xie, J., Zhang, T., Sang, S., Islam, M. T., Wang, J.-Y., Chen, C., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101146 · Cited by 120
Self-citationChemotherapy use and survival among young and middle-aged patients with gastric cancer
Jiang, Y., Xie, J., Huang, W., Chen, H., Xi, S., Li, T., Chen, C., Sun, Z., Hu, Y., Liu, W., et al. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000253 · Cited by 18
Self-citation
Metadata
- Authors
- Jiang, Y., Yuan, Q., Lv, W., Xi, S., Huang, W., Sun, Z., Chen, H., Zhao, L., Liu, W., Hu, Y., Lu, L., Ma, J., Li, T., Yu, J., Wang, Q., & Li, G.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2018
- Volume
- 8
- Issue
- 21
- Pages
- 5915-5928
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2903016288
- Cited by
- 125
- References
- 13
- FWCI
- 9.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.